Trials / Completed
CompletedNCT02204046
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast
A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Adenocarcinoma of the Breast
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study were to assess the safety and tolerability of intravenously (i.v.) administered 186Rhenium (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of 186Re-labelled bivatuzumab in patients with adenocarcinoma of the breast
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIWA 4 |
Timeline
- Start date
- 2000-01-01
- Primary completion
- 2001-02-01
- First posted
- 2014-07-30
- Last updated
- 2014-07-30
Source: ClinicalTrials.gov record NCT02204046. Inclusion in this directory is not an endorsement.